Surgery study for hemophilia A patients using Altuvoct
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at how people with hemophilia A do when they have surgery while using the medicine Altuvoct (efanesoctocog alfa). It helps doctors learn more about surgical practices for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hemophilia A.
- You are scheduled for surgery that will use Altuvoct.
- You agree to be in the study after reading about it.
- You do not have any other bleeding disorder.
- You do not have factor VIII inhibitors.
- You do not have severe liver or kidney disease.
- You are not allergic to Altuvoct or its ingredients.
- You are not in another clinical trial (but other types of studies are okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This study tests how well and how safely Octapharma’s clotting factor products (Nuwiq, Octanate, or Wilate) work in people with Hemophilia A who are newly treated or have had very few clotting factor doses. It also looks at how often side effects occur and how the treatments are used in real care.
This study follows male participants with hemophilia A who are already taking Esperoct® as preventive (regular) treatment. It aims to learn how well this medicine works in real-world use and monitor safety over time.
This study tests an experimental oral medication (Inno8) for people with hemophilia A. It aims to find the best dose and see how the body handles it. You may be able to join if you have mild to severe hemophilia A and are not on other preventive treatments.
This study tests a treatment called Altuviiio for children with severe hemophilia A who have developed inhibitors (antibodies that block factor replacement). The goal is to help the body become tolerant to factor therapy again, preventing bleeding episodes.
This study watches how well damoctocog alfa pegol (a medicine to help blood clot) works in children with hemophilia A. It is for kids ages 7 to 12 who have used factor VIII before and do not have inhibitors (antibodies that stop the medicine from working).
Hear when a new Haemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.